Viking Therapeutics - VKTX Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued twelve-month price targets for Viking Therapeutics' shares. Their VKTX share price forecasts range from $10.00 to $15.00. On average, they expect the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 295.9% from the stock's current price.
View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts.

Viking Therapeutics' stock was trading at $4.60 at the start of the year. Since then, VKTX stock has decreased by 25.9% and is now trading at $3.41.
View the best growth stocks for 2022 here.

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our VKTX earnings forecast.

Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. During the same period last year, the firm earned ($0.13) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Walleye Capital LLC (0.39%), Connor Clark & Lunn Investment Management Ltd. (0.29%), Summit Financial Wealth Advisors LLC (0.04%), Pinnacle Wealth Planning Services Inc. (0.04%), Envestnet Asset Management Inc. (0.02%) and 180 Wealth Advisors LLC (0.02%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends.

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VKTX stock can currently be purchased for approximately $3.41.

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $261.51 million. The biotechnology company earns $-54,990,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

Viking Therapeutics employs 17 workers across the globe.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.